ELECTROMEDICAL TECH INC - EMED STOCK NEWS

Electromedical Technologies, Inc. (OTC: EMED) has appointed David Orn as the new Director of Business and Sales Development. This strategic move aims to expand sales and distribution for their flagship product, the Wellness Pro Plus device. Orn brings extensive experience from the medical industry, having worked with companies like Zimmer Biomet and Medtronic. CEO Matthew Wolfson expressed confidence in Orn's capabilities to help achieve the company's growth targets. Electromedical focuses on bioelectronic devices for chronic pain relief, with a commitment to drug-free therapies.

Electromedical Technologies, Inc. (OTC: EMED) shares promising insights in its Annual Letter to Shareholders, highlighting key operational and financial milestones in 2021. The company successfully reduced convertible debt and secured an equity line to enhance product development. Progress includes the Wellness Pro POD Prototype in functionality testing, with plans for regulatory submission in mid-2022. An increase in sales representatives positions EMED for future growth, and ongoing partnerships aim to broaden distribution. The market for drug-free pain relief continues to expand, supporting Electromedical's growth strategy.

Electromedical Technologies (EMED) reported strong Q3 2021 results with revenues of $301,157, up 46% from Q3 2020. The gross margin rose to 78%, while SG&A expenses decreased by 80% to $0.4M. Despite a net loss of $3.3M, the company expressed optimism about ongoing marketing initiatives and the development of its WellnessPro POD product. Additionally, ongoing efforts to settle convertible debt aim to enhance financial stability. EMED plans to improve its financial metrics as it prepares for potential uplisting in the near future.

Electromedical Technologies, Inc. (OTCQB: EMED) has successfully passed the ISO 13485:2016 recertification audit for Medical Device and Quality Management Systems. This certification highlights the company's commitment to quality and safety in its production of bioelectronic devices for pain relief. The company is currently in Phase 2 of developing the WellnessPro POD, a professional-grade wearable device aimed at mass-market retail customers. The effectiveness of this device will be tested before submission to the FDA for 510(k) clearance.

Electromedical Technologies, Inc. (OTCQB: EMED) reported its financial results for the six months ending June 30, 2021. Revenue increased to $369,394, a 5% rise from the previous year. However, selling, general, and administrative expenses surged by 55% to $2,367,254, resulting in a net loss from operations of ($2,089,192) compared to ($1,255,702) in 2020. Total net loss also escalated to ($3,334,916) or ($0.10) per share, from ($1,291,496) or ($0.07) per share in 2020.

Electromedical Technologies (OTCQB: EMED) reported a 48% increase in revenue for Q2 2021, amounting to $202,954, compared to $136,755 in Q2 2020. The company saw a 28% decline in Selling, General, and Administrative expenses, bringing them to $677,781. Net loss from operations improved to ($524,658), down from ($817,909) in the previous year. For the six months ended June 30, 2021, revenue rose 5% to $369,394. Despite improvements, total net loss increased to ($3,334,916), or ($0.10) per share, from ($1,291,496) in the same period last year.

Electromedical Technologies is expanding its research into Alzheimer's Disease therapy using bioelectronics. Led by Dr. Sholpan Askarova, this initiative aims to discover neuroprotective electrical frequencies as alternatives to ineffective pharmaceuticals. With around 44 million people suffering from Alzheimer's globally, the market is projected to reach $13.3 billion in 2023. The company plans to collaborate with Nazarbayev University to advance this critical research, which includes developing non-invasive treatments leveraging bioelectronic devices.

Electromedical Technologies (OTCQB: EMED) announced that Director Kathy Strand R.N. will showcase the company's flagship device, WellnessPro Plus®, at the Parker Seminars Expo in Orlando from June 11-13, 2021. The event aims to enhance brand awareness and recruit new sales representatives. The expo will feature high-profile speakers, including the U.S. Surgeon General, and offers a unique platform for educating chiropractors about bioelectronic devices. The company anticipates this exposure will contribute to future sales growth.

Electromedical Technologies (OTCQB: EMED) has announced the completion of an agreement with Nazarbayev University to expand collaborative research on electro-modulation therapies. The focus is on how these therapies can influence cell signaling to develop next-generation bioelectronic devices aimed at treating chronic pain and other conditions. The research aims to decipher the effects of electrical fields on cellular responses. The initiative is set to lead to an Investigational Device Exemption (IDE) process with the FDA.